Neoadjuvant anti-programmed death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial
Immunotherapies targeting the PD1/PD-L1 pathway have had a large impact on the treatment of advanced NSCLC. Concerning multimodality tumor therapy, only few trials until today have been performed investigating neoadjuvant treatment with anti PD-1 immunotherapy prior to curative intent surgery. Aim o...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
02 May 2019
|
| In: |
BMC cancer
Year: 2019, Jahrgang: 19 |
| ISSN: | 1471-2407 |
| DOI: | 10.1186/s12885-019-5624-2 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1186/s12885-019-5624-2
|
| Verfasserangaben: | Florian Eichhorn, Laura V. Klotz, Helge Bischoff, Michael Thomas, Felix Lasitschka, Hauke Winter, Hans Hoffmann and Martin E. Eichhorn |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1691886505 | ||
| 003 | DE-627 | ||
| 005 | 20220818010655.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200309s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12885-019-5624-2 |2 doi | |
| 035 | |a (DE-627)1691886505 | ||
| 035 | |a (DE-599)KXP1691886505 | ||
| 035 | |a (OCoLC)1341309808 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Eichhorn, Florian |d 1984- |e VerfasserIn |0 (DE-588)143005952 |0 (DE-627)641429045 |0 (DE-576)334573483 |4 aut | |
| 245 | 1 | 0 | |a Neoadjuvant anti-programmed death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC) |b the NEOMUN trial |c Florian Eichhorn, Laura V. Klotz, Helge Bischoff, Michael Thomas, Felix Lasitschka, Hauke Winter, Hans Hoffmann and Martin E. Eichhorn |
| 246 | 3 | 0 | |a one second third |
| 264 | 1 | |c 02 May 2019 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 10.03.2020 | ||
| 520 | |a Immunotherapies targeting the PD1/PD-L1 pathway have had a large impact on the treatment of advanced NSCLC. Concerning multimodality tumor therapy, only few trials until today have been performed investigating neoadjuvant treatment with anti PD-1 immunotherapy prior to curative intent surgery. Aim of the NEOMUN investigator initiated trial (EudraCT-Number: 2017-000105-20; ClinicalTrials.govIdentifier: NCT03197467) is to assess feasibility and safety of pre-surgical anti PD-1 treatment in order to improve long term survival. | ||
| 700 | 1 | |a Klotz, Laura Valentina |d 1983- |e VerfasserIn |0 (DE-588)143075101 |0 (DE-627)641874685 |0 (DE-576)334894921 |4 aut | |
| 700 | 1 | |a Bischoff, Helge |d 1958- |e VerfasserIn |0 (DE-588)111184576 |0 (DE-627)389658286 |0 (DE-576)167287249 |4 aut | |
| 700 | 1 | |a Thomas, Michael |e VerfasserIn |0 (DE-588)1054438781 |0 (DE-627)79152213X |0 (DE-576)41027089X |4 aut | |
| 700 | 1 | |a Lasitschka, Felix |d 1979- |e VerfasserIn |0 (DE-588)140496343 |0 (DE-627)618903542 |0 (DE-576)318526077 |4 aut | |
| 700 | 1 | |a Winter, Hauke |e VerfasserIn |0 (DE-588)1162076038 |0 (DE-627)1025509773 |0 (DE-576)176791531 |4 aut | |
| 700 | 1 | |a Hoffmann, Hans |d 1957- |e VerfasserIn |0 (DE-588)1022900455 |0 (DE-627)71732852X |0 (DE-576)366147730 |4 aut | |
| 700 | 1 | |a Eichhorn, Martin E. |d 1974- |e VerfasserIn |0 (DE-588)124436900 |0 (DE-627)363346627 |0 (DE-576)294170545 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC cancer |d London : BioMed Central, 2001 |g 19(2019) Artikel-Nummer 413, 8 Seiten |h Online-Ressource |w (DE-627)326643710 |w (DE-600)2041352-X |w (DE-576)107014645 |x 1471-2407 |7 nnas |a Neoadjuvant anti-programmed death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC) the NEOMUN trial |
| 773 | 1 | 8 | |g volume:19 |g year:2019 |g extent:10 |a Neoadjuvant anti-programmed death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC) the NEOMUN trial |
| 856 | 4 | 0 | |u https://doi.org/10.1186/s12885-019-5624-2 |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200309 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 124436900 |a Eichhorn, Martin E. |m 124436900:Eichhorn, Martin E. |d 910000 |d 950000 |d 950900 |e 910000PE124436900 |e 950000PE124436900 |e 950900PE124436900 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 8 |y j | ||
| 998 | |g 1022900455 |a Hoffmann, Hans |m 1022900455:Hoffmann, Hans |d 910000 |d 950000 |d 950900 |e 910000PH1022900455 |e 950000PH1022900455 |e 950900PH1022900455 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 7 | ||
| 998 | |g 1162076038 |a Winter, Hauke |m 1162076038:Winter, Hauke |d 910000 |d 950000 |d 950900 |e 910000PW1162076038 |e 950000PW1162076038 |e 950900PW1162076038 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 6 | ||
| 998 | |g 140496343 |a Lasitschka, Felix |m 140496343:Lasitschka, Felix |d 910000 |d 912000 |e 910000PL140496343 |e 912000PL140496343 |k 0/910000/ |k 1/910000/912000/ |p 5 | ||
| 998 | |g 1054438781 |a Thomas, Michael |m 1054438781:Thomas, Michael |d 910000 |d 950000 |d 950900 |e 910000PT1054438781 |e 950000PT1054438781 |e 950900PT1054438781 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 4 | ||
| 998 | |g 111184576 |a Bischoff, Helge |m 111184576:Bischoff, Helge |d 910000 |d 950000 |d 950900 |e 910000PB111184576 |e 950000PB111184576 |e 950900PB111184576 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 3 | ||
| 998 | |g 143075101 |a Klotz, Laura Valentina |m 143075101:Klotz, Laura Valentina |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PK143075101 |e 950000PK143075101 |e 950900PK143075101 |e 50000PK143075101 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 2 | ||
| 998 | |g 143005952 |a Eichhorn, Florian |m 143005952:Eichhorn, Florian |d 910000 |d 950000 |d 950900 |e 910000PE143005952 |e 950000PE143005952 |e 950900PE143005952 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 1 |x j | ||
| 999 | |a KXP-PPN1691886505 |e 360529989X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"10 S."}],"id":{"eki":["1691886505"],"doi":["10.1186/s12885-019-5624-2"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 10.03.2020"],"relHost":[{"pubHistory":["1.2001 -"],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"recId":"326643710","disp":"Neoadjuvant anti-programmed death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC) the NEOMUN trialBMC cancer","note":["Gesehen am 22.05.20"],"physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["326643710"],"zdb":["2041352-X"],"issn":["1471-2407"]},"part":{"volume":"19","text":"19(2019) Artikel-Nummer 413, 8 Seiten","extent":"10","year":"2019"},"title":[{"title":"BMC cancer","title_sort":"BMC cancer"}],"origin":[{"publisher":"BioMed Central ; Springer","dateIssuedDisp":"2001-","dateIssuedKey":"2001","publisherPlace":"London ; Berlin ; Heidelberg"}]}],"person":[{"role":"aut","display":"Eichhorn, Florian","given":"Florian","family":"Eichhorn"},{"role":"aut","family":"Klotz","display":"Klotz, Laura Valentina","given":"Laura Valentina"},{"family":"Bischoff","given":"Helge","display":"Bischoff, Helge","role":"aut"},{"role":"aut","given":"Michael","display":"Thomas, Michael","family":"Thomas"},{"given":"Felix","display":"Lasitschka, Felix","family":"Lasitschka","role":"aut"},{"role":"aut","family":"Winter","display":"Winter, Hauke","given":"Hauke"},{"role":"aut","family":"Hoffmann","given":"Hans","display":"Hoffmann, Hans"},{"display":"Eichhorn, Martin E.","given":"Martin E.","family":"Eichhorn","role":"aut"}],"name":{"displayForm":["Florian Eichhorn, Laura V. Klotz, Helge Bischoff, Michael Thomas, Felix Lasitschka, Hauke Winter, Hans Hoffmann and Martin E. Eichhorn"]},"origin":[{"dateIssuedDisp":"02 May 2019","dateIssuedKey":"2019"}],"recId":"1691886505","title":[{"title":"Neoadjuvant anti-programmed death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC)","title_sort":"Neoadjuvant anti-programmed death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC)","subtitle":"the NEOMUN trial"}],"language":["eng"]} | ||
| SRT | |a EICHHORNFLNEOADJUVAN0220 | ||